| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 2.6, positive 3.1, negative -0.5) on 20251028. The forces of Price Level (2), Sentiment towards Fundamentals (2), Option Speculation (1.5), Broad Market Trend (0.5), Sector Price Trend (0.2), and Valuation Sentiment (-1) will drive up the price. The forces of and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (3.1). The extreme bullish overall sentiment (2.6) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-28 | 2% | 1% | 145.44 | 74 | -0.65% | 0.21% | 1.8 | 0.2 | 2 | 5.2 |
| 2025-10-27 | 1% | 1% | 146.38 | 87 | 0.23% | 0.35% | 1.5 | 0.3 | 1.9 | 2.9 |
| 2025-10-26 | 1% | 1% | 1.3 | 0.4 | 2 | 1 | ||||
| 2025-10-25 | 0% | 0.9% | 1.3 | 0.4 | 2 | 0 | ||||
| 2025-10-24 | 1% | 0.9% | 146.05 | 79 | 0.01% | 0.28% | 1.4 | 0.4 | 2.2 | 0.9 |
| 2025-10-23 | 1% | 1% | 146.04 | 79 | 0.02% | 0.07% | 1.5 | 0.7 | 2.3 | 3.7 |
| 2025-10-22 | 1% | 1% | 146 | 79 | 0.65% | 0.14% | 1.3 | 0.7 | 2.3 | 1.2 |
| 2025-10-21 | 2% | 1.1% | 145.06 | 75 | 0.21% | 0.07% | 1.5 | 0.6 | 2.4 | 4.4 |
| 2025-10-20 | 1% | 1.1% | 144.76 | 75 | 1.06% | 0% | 1.3 | 0.5 | 2.5 | 6.3 |
| 2025-10-19 | 0% | 1% | 1.5 | 0 | 2.5 | 0 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (7) UnitedHealth Earnings Top Expectations, as Insurer Works Toward a Turnaround The health care giant topped earnings estimates and raised its 2025 guidance after a series of setbacks. (https://www.investopedia.com/) Tue. Oct 28, 2025 | |
| 2 (5) Sticking With This Labcorp Price Target as Shares Take a Hit Timing issues are weighing on the shares, but we continue to like the long-term narrative. (https://www.thestreet.com/) Tue. Oct 28, 2025 | |
| 3 (6) US Obesity Rate Sees Decline As Weight Loss Drugs Gain Ground According to the Gallup National Health and Well-Being Index, the share of adults in the U.S. who are obese dropped slightly from 39.9 percent in 2022 to 37 percent in 2025, signifying a small but meaningful decline after years of little change. (https://www.rttnews.com/) Tue. Oct 28, 2025 | |
| 4 (8) Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support Labcorp posts Q3 EPS of $4.18 and sales of $3.56 billion, exceeding estimates, while revising 2025 guidance amid strong diagnostics and lab growth. (https://www.benzinga.com/) Tue. Oct 28, 2025 | |
| 5 (8) Lilly partners with Nvidia on AI supercomputer to speed up drug development Using the supercomputer, scientists at Lilly will be able to train AI models on millions of experiments to test potential medicines, expanding the scope of drug discovery efforts, the company said. A number of these proprietary AI models will be available on Lilly TuneLab, a federated artificial-intelligence and machine-learning platform that allows biotech companies access to drug discovery models trained on years of its research data. The federated model is a privacy-preserving approach that enables biotechs to tap into Lilly's AI models without directly exposing either their or Lilly's proprietary data. (https://finance.yahoo.com/) Tue. Oct 28, 2025 | |
| 6 (-6) Philips Gets Warning Letter From US FDA on Device Facilities Royal Philips NV received a letter from the US Food and Drug Administration warning that three manufacturing sites don’t meet standards, a blow to efforts to draw a line under high-profile issues with some of its products. (https://www.bloomberg.com/) Tue. Oct 28, 2025 | |
| 7 (0) Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week. (https://www.cnbc.com/) Tue. Oct 28, 2025 | |
| 8 (7) UnitedHealth Delivers The Quarter Tepper, Burry Have Been Waiting For UnitedHealth Group Inc (UNH) reported strong earnings, giving David Tepper and Michael Burry led hedge funds hope for the future. (https://www.benzinga.com/) Tue. Oct 28, 2025 | |
| 9 (8) UnitedHealth Revenue Rises as Turnaround Efforts Continue The healthcare giant reported revenue rose more than 10%, and its CEO said he was confident of solid earnings growth next year. (https://finance.yahoo.com/) Tue. Oct 28, 2025 | |
| 10 (6) UnitedHealth tops 3Q forecasts as it resets coverage prices to deal with rising costs UnitedHealth has returned to better-than-expected growth after starting the year swamped by medical costs and then withdrawing its forecast for 2025. In the meantime, UnitedHealth is going through a transition year, resetting health insurance prices and trimming unprofitable parts of that business. With 8.4 million customers, UnitedHealth is the nation’s largest provider of Medicare Advantage plans. (https://finance.yahoo.com/) Tue. Oct 28, 2025 | |
| 11 (8) Lilly Makes Billions of Weight-Loss Pills Before US Approval Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global demand ahead of a potential launch next year. (https://www.bloomberg.com/) Tue. Oct 28, 2025 | |
| 12 (8) UnitedHealth lifts 2025 profit forecast, aims for growth in 2026 UnitedHealth raised its annual profit forecast and said it aims to grow in 2026, in a sign that the turnaround efforts were gaining steam. (https://www.cnbc.com/) Tue. Oct 28, 2025 | |
| 13 (5) Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done' Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC. (https://www.cnbc.com/) Tue. Oct 28, 2025 | |
| 14 (8) UnitedHealth Lifts Outlook As CEO Promises 'Durable Growth' Ahead UnitedHealth stock rises after Q3 earnings beat expectations and the company lifts its 2025 guidance, signaling confidence in future growth. (https://www.benzinga.com/) Tue. Oct 28, 2025 | |
| 15 (0) Trump in Japan; UnitedHealth raises outlook; gold drops - what’s moving markets Trump in Japan; UnitedHealth raises outlook; gold drops - what’s moving markets (https://www.investing.com/) Tue. Oct 28, 2025 | |
| 16 (-6) CSL Drops After Delaying Seqirus Spinoff on US Vaccine Market CSL Ltd. shares slumped after Australia’s largest drugmaker scrapped plans to complete a demerger of its Seqirus vaccines business by June 2026, citing heightened volatility in the US influenza vaccine market that it said would prevent the move from realizing full value for shareholders. (https://www.bloomberg.com/) Mon. Oct 27, 2025 | |
| 17 (8) Novartis Q3 preview: BofA sees strong product momentum, potential EBIT Upgrade Novartis Q3 preview: BofA sees strong product momentum, potential EBIT Upgrade (https://www.investing.com/) Mon. Oct 27, 2025 | |
| 18 (7) Edwards Lifesciences Corp. stock outperforms competitors on strong trading day Shares of Edwards Lifesciences Corp. EW rose 6.20% to $80.82 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.23% to 6,875.16 and the Dow Jones Industrial Average DJIA rising 0.71% to 47,544.59. The stock's rise snapped a two-day losing streak. (https://www.marketwatch.com/) Mon. Oct 27, 2025 | |
| 19 (3) HCA Healthcare Inc. stock underperforms Monday when compared to competitors despite daily gains Shares of HCA Healthcare Inc. HCA rallied 4.66% to $467.86 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.23% to 6,875.16 and the Dow Jones Industrial Average DJIA rising 0.71% to 47,544.59. This was the stock's second consecutive day of gains. (https://www.marketwatch.com/) Mon. Oct 27, 2025 | |
| 20 (0) UnitedHealth Group is due to report on Tuesday. Here’s what to expect. UnitedHealth Group is due to report on Tuesday. Here’s what to expect. (https://www.investing.com/) Mon. Oct 27, 2025 | |
| 21 (8) 3 Healthcare Stocks to Buy Hand Over Fist in October One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close. (https://www.fool.com/) Mon. Oct 27, 2025 | |
| 22 (-5) Cigna Will End Drug Rebates in Many Private Health Plans in 2027 Cigna Group will eliminate prescription drug rebates in many of its commercial health plans in 2027, upending an opaque, controversial practice that’s drawn the ire of President Donald Trump. (https://www.bloomberg.com/) Mon. Oct 27, 2025 | |
| 23 (0) Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk Here are five key things investors need to know to start the trading day. (https://www.cnbc.com/) Mon. Oct 27, 2025 | |
| 24 (7) EXCLUSIVE: Co-Diagnostics Inks JV With Saudi Arabia Firm For Middle East Market Co-Diagnostics (Nasdaq: CODX) entered a joint venture with Arabian Eagle Manufacturing to develop and commercialize Co-Dx technologies in Saudi Arabia and other Middle East and North Africa countries. (https://www.benzinga.com/) Mon. Oct 27, 2025 | |
| 25 (7) USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks Rare earths companies CRML, MP, USA Rare Earth (USAR) and Lynas (LYC.AX, LYSDY, LYSCF, LYI.MU, LYIC.BE) fall on U.S.-China trade optimism. Softbank (9984.T, 3AG1.F, SFTBY, SFT.VI, SFTU.SG) approves the final chunk in one of the biggest ever AI investments: $22.5 billion in OpenAI. IREN, the crypto miner now providing computing power for AI, is up around 900% in six months. Novartis (NVS, NOVN.SW, NOT.F, NOT.MU, NOVNN.MX) plans to acquire a Californian biotech firm (RNA) for $12 billion. And Porsche (PAH3.DE, 1PORS.MI, POAHY) follows GM and Ford (F) in shifting its strategy away from EV's. For more live coverage of markets watch the full episode of Market Sunrise and head to Yahoo Finance. (https://finance.yahoo.com/) Mon. Oct 27, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA